Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON.
Publication
, Journal Article
Pun, PH; Crowley, ST
Published in: Kidney360
January 28, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Kidney360
DOI
EISSN
2641-7650
Publication Date
January 28, 2021
Volume
2
Issue
1
Start / End Page
13 / 15
Location
United States
Related Subject Headings
- Renal Insufficiency, Chronic
- Nephrogenic Fibrosing Dermopathy
- Humans
- Gadolinium
- Contrast Media
- 4202 Epidemiology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pun, P. H., & Crowley, S. T. (2021). Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON. Kidney360, 2(1), 13–15. https://doi.org/10.34067/KID.0005572020
Pun, Patrick H., and Susan T. Crowley. “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON.” Kidney360 2, no. 1 (January 28, 2021): 13–15. https://doi.org/10.34067/KID.0005572020.
Pun PH, Crowley ST. Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON. Kidney360. 2021 Jan 28;2(1):13–5.
Pun, Patrick H., and Susan T. Crowley. “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON.” Kidney360, vol. 2, no. 1, Jan. 2021, pp. 13–15. Pubmed, doi:10.34067/KID.0005572020.
Pun PH, Crowley ST. Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON. Kidney360. 2021 Jan 28;2(1):13–15.
Published In
Kidney360
DOI
EISSN
2641-7650
Publication Date
January 28, 2021
Volume
2
Issue
1
Start / End Page
13 / 15
Location
United States
Related Subject Headings
- Renal Insufficiency, Chronic
- Nephrogenic Fibrosing Dermopathy
- Humans
- Gadolinium
- Contrast Media
- 4202 Epidemiology
- 3202 Clinical sciences